Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (September 2020)
29 slides from Sutro Biopharma's investor presentation, September 2020
Slide 1: Company Overview
Company Overview September 2020 NASDAQ: STRO Bill Newell, CEO NON-CONFIDENTIAL
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: The Sutro Vision
The Sutro Vision Novel Platform Delivering on Promise to Change the Future of Oncology PLATFORM PRODUCTS PARTNERS XpressCF® and Proven IND Engine Premier Collaborations with Robust XpressCF+™ Economics: • 3 Potential Best-in-Class ADCs in Phase 1 • Precision Protein • 2 more INDs projected before YE
Slide 4: Sutro's Approach
Sutro’s Approach Delivering Potentially Best-in-Class ADCs and Cytokine Conjugates Widening the Therapeutic Index is Key to Achieving Optimized Performance The Sutro Advantage XpressCF® – Our Truly Empirical Approach • Rapid iterative design Proprietary XpressCF® rapid synthesis protein library gene
Slide 5: Sutro Clinical Pipeline
Sutro Clinical Pipeline Owned and Partnered Programs Program Discovery Preclinical Phase 1/1b Phase 2/3 Milestone Commercial Rights Clinical Data Presented FolRα - Targeting ADC Sep 2020 Ovarian and Endometrial Cancer Commence Dose Expansion STRO-002 Phase in 2H 2020 CD74 - Targeting ADC Lymphomas;
Slide 6: Encouraging Progress Across Multiple Programs
Encouraging Progress Across Multiple Programs* STRO-002 (FolRα ADC) – OC all comers CC-99712 (BCMA ADC) – MM all comers Dose escalation enrollment complete (39 patients Dose escalation on-going (cleared 0.5-2.0 mg/kg) enrolled, 34 ≥ 2.9 mg/kg & 38% remain on study) • N=8 as of June 2020 includes 4 p
Slide 7: Delivering On Our Collaborations
Delivering On Our Collaborations ~ $384 Million in Payments Received through June 30, 2020 from Collaborators BCMA-targeting ADC (CC-99712): IND Anticipated in 2H2021: • Phase 1b/2 trial for multiple myeloma (dose escalation • Formerly SutroVax – spinout using XpressCF+™ began 2H 2019) • Potential b
Slide 8: FolRα – Targeting ADC Phase 1
STRO 002 FolRα – Targeting ADC Phase 1 Potential Best-in-Class ADC for Ovarian and Endometrial Cancers NON-CONFIDENTIAL
Slide 9: STRO-002 Structure and Design
STRO 002 STRO-002 Structure and Design Optimized molecule provides potential for best-in-class • STRO-002 is a novel homogeneous antibody drug conjugate using precisely positioned non-natural amino acids • STRO-002 has a drug-antibody ratio of 4:1, with a proprietary cleavable hemiasterlin linker-wa
Slide 10: Heavily Pretreated Ovarian Cancer Patients: Demographics/Dose Levels
STRO 002 Heavily Pretreated Ovarian Cancer Patients: Demographics/Dose Levels Data as of August 31, 2020 Characteristic Total N = 39 (%) Characteristic Total N = 39 (%) Age, median (range), years 61 (48-79) Dose Level of STRO-002 Tumor type 0.5 mg/kg, 1.0 mg/kg, 1.8 mg/kg 5 (13) EOC 30 (77) Fallopia
Slide 11: STRO-002 is Generally Well Tolerated
STRO-002 is Generally Well Tolerated Safety Profile Is Encouraging • 87% of AEs were Grade 1–2 • No need for prophylactic corticosteroid eyedrops • Neutropenia readily reverses within 1 week, without the need for G-CSF • Peripheral neuropathy/arthralgia can be managed with dose reduction/delay witho
Slide 12: Robust Anti-Tumor Activity in Heavily Pre-Treated, Unselected Patients
Robust Anti-Tumor Activity in Heavily Pre-Treated, Unselected Patients Best % change in sum of target lesions from baseline 50 Evaluable patients treated at ≥ 2.9 mg/kg, N=29 40 +30 30 +19 20 +13 10 +6 +6 +4 +2 +1 0 -2 -3 -5 -6 -6 -11 -18 -19 -21 -22 -22 -26 -29 -32 -32 -33 -35 -44 -48 -74 -88 0 -10
Slide 13: Partial Response Achieved in 24% of Unenriched, Heavily Pre-Treated Ovarian Cancer Patients
Partial Response Achieved in 24% of Unenriched, Heavily Pre-Treated Ovarian Cancer Patients 2.9 mg/kg 1st PR - week 6 cPR 6.0 mg/kg 1st PR - week 14 5.2 mg/kg uPR 1st PR - 6.0 mg/kg 4.3 mg/kg (after delay – DLT) week 36 uPR 6.0 mg/kg 5.2 PR - 4.3 week 22 mg/kg uPR mg/kg = Dose reduction 5.2 cPR = Co
Slide 14: Partial Response with 74% Tumor Reduction
Partial Response with 74% Tumor Reduction Patient Continues on Treatment Baseline Confirmed PR after 4 cycles 3/16/20 06/29/20 57-year-old woman with platinum resistant ovarian cancer progressing after 4 prior regimens received STRO-002 at 5.2 mg/kg and remains on study treatment 14 NON-CONFIDENTIAL
Slide 15: Long Duration on Study and Disease Control Observed
STRO 002 Long Duration on Study and Disease Control Observed in Unenriched, Heavily Pre-Treated Ovarian Cancer Patients 2.9 mg/kg cPR 2.9 mg/kg cSD 4.3 mg/kg 4.3 mg/kg cSD cSD ORR: 24% (8/33) 6.0 mg/kg uPR 6.0 mg/kg uPR 5.2 mg/kg cSD 6.0 mg/kg uPR 4.3 mg/kg 5.2 mg/kg cSD cSD DCR at ≥ 12 weeks: 6.0 m
Slide 16: High Rates of CA-125 Responses are Associated with Anti-Tumor Activity
High Rates of CA-125 Responses are Associated with STRO 002 Anti-Tumor Activity Y axis- change from C1D1 CA-125 72% (18/25) of patients with elevated 100% CA-125 levels at baseline had ≥ 50% reduction in CA-125 in at least 1 post-treatment timepoint 50% Change from C1D1 • 10/25 (40%) have confirmed
Slide 17: Improved Efficacy Outcomes Observed as Data Matures
Improved Efficacy Outcomes (Increased ORR and DCR) STRO 002 Observed as Data Matures with Longer Follow-Up STRO-002 Clinical Data Readout April 20th, 2020 Interim Analysis August 31st, 2020 Interim Analysis N ≥ 2.9 mg/kg* 25 (20 evaluable) 34 (33 evaluable) Median Age 61 (47–76) 61 (48–79) Median Pr
Slide 18: Summary and Next Steps in Clinical Development
STRO 002 Summary and Next Steps in Clinical Development • STRO-002 is clinically efficacious at multiple doses, starting at 2.9 mg/kg • Dose reductions or delays were not associated with loss of anti-tumor activity • Further dose optimization will be explored during dose expansion • Anticipate RP2D
Slide 19: CD74-Targeting ADC: Phase 1
STRO 001 CD74-Targeting ADC: Phase 1 Potential First and Best-in-Class ADC for B-Cell Malignancies NON-CONFIDENTIAL
Slide 20: STRO-001 Structure and Design
STRO 001 STRO-001 Structure and Design First-in-class Molecule with Potential for Improved Patient Outcomes • STRO-001 is a novel homogeneous antibody-drug conjugate using precisely positioned non-natural amino acids • STRO-001 comprises two non-cleavable maytansinoid linker-warheads (DAR=2) that ar
Slide 21: Patient Demographics
STRO 001 Patient Demographics First 25 Patients – ASH Abstract November 2019 Characteristics Cohort A (MM) Cohort B (NHL) Total N =14 N=11 N=25 Age, median (range), years 64.5 (42–80) 64 (21–82) 64 (21–82) Median time from diagnosis in years (range) 6.4 (1.3–13.6) 3.2 (1.0–29.8) 6.2 (1.0–29.8) Disea
Slide 22: Generally Well Tolerated with Early Signs of Anti-Tumor Activity
STRO 001 Generally Well Tolerated with Early Signs of Anti-Tumor Activity Presented at EHA June 2019 and Updated in ASH Abstract November 2019 • STRO-001 was generally well tolerated, most AEs were Grade 1 & 2 • No ocular toxicity signals have been observed • Preliminary anti-tumor activity: DLBCL:
Slide 23: CC–99712 (BCMA-Targeting ADC) Phase 1B/2 Study
CC–99712 (BCMA-Targeting ADC) Phase 1B/2 Study Potential for Best-In-Class CC-99712 Molecule Ongoing Study of Dose Escalation (Q3W) Site-specific conjugation leads to Drug-antibody Ratio (DAR) = 4 DL7 10.0 mg/kg DL6 6.7 mg/kg N=3-6 DL5 4.5 mg/kg N=4 DL4 3.0 mg/kg O O O O O O O N = 2 DL3 2.0 mg/kg O
Slide 24: M1231 (MUC1-EGFR Bispecific ADC)
M1231 (MUC1-EGFR Bispecific ADC) Potential for First-In-Class – 1Q21 First In Human Planned • First bispecific ADC to go to clinic; M1231 targets MUC1 & EGFR EGFR • Combines next generation technologies; stable site-specific XpressCF+™ conjugation, optimized positioning of a MUC1 proprietary hemiast
Slide 25: M1231: Strong efficacy in preclinical NSCLC & esophageal cancer PDX models
M1231 (MUC1-EGFR Bispecific ADC) Strong efficacy in preclinical NSCLC & esophageal cancer PDX models • A single M1231 application was associated with complete remission in a subset of preclinical NSCLS and sqCC esophageal PDX models • Tumor response seems to be associated with target expression Sour
Slide 26: Sutro's Next Generation Tumor Targeting Immunostimulatory ADC
iADC Sutro’s Next Generation Tumor Targeting Immunostimulatory ADC Off the shelf, systemically administered in situ immunization • Breakthrough technology for dual conjugated immunostimulatory antibody drug conjugate • Designed and enabled using Sutro’s XpressCF+TM platform • Enables simultaneous an
Slide 27: Immunostimulatory ADC Provides Enhanced Immune Cell Activation and Anti-Tumor Immunity
Immunostimulatory ADC Provides Enhanced iADC Immune Cell Activation and Anti-Tumor Immunity MC38-hFolR mouse model iADC single dose causes iADC treated mice resistant to some complete responses future re-challenge Control (iADC) ISAC (TLR agonist alone) ADC (Cytotoxin alone) iADC (Cytotoxin + TLR ag
Slide 28: Experienced Leadership Team
Experienced Leadership Team Trevor Hallam, PhD Arturo Molina, Ed Albini Chief Scientific Officer MD, MS, FACP Chief Financial Officer Chief Medical Officer William Newell, JD Chief Executive Officer and Member of the Board of Directors Shabbir Anik, PhD Linda Fitzpatrick Nicki Vasquez, PhD Chief Tec
Slide 29: Company Overview
Company Overview September 2020 NASDAQ: STRO Bill Newell, CEO NON-CONFIDENTIAL
Sutro Biopharma — Investor Presentation (September 2020) on 6ix